To overcome said issue, in the reference therapy for BRAF-mutated metastatic melanoma, BRAF inhibitors are used in combination with MEK inhibitors to act simultaneously against two different targets of the same pathway, evading the cancerous cell-intrinsic resistance [3,8,9,20]. The gene discussed is BRAF; the disease is metastatic melanoma.